• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect . COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

tetano

Editor, Senior Moderator
J Infect


. 2020 Aug 24;S0163-4453(20)30563-6.
doi: 10.1016/j.jinf.2020.08.036. Online ahead of print.
COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity


Marie Kroemer[SUP] 1 [/SUP], Laurie Spehner[SUP] 2 [/SUP], Lucie Vettoretti[SUP] 3 [/SUP], Adeline Bouard[SUP] 4 [/SUP], Guillaume Eberst[SUP] 5 [/SUP], Sebastien Pili Floury[SUP] 6 [/SUP], Gilles Capellier[SUP] 7 [/SUP], Quentin Lepiller[SUP] 8 [/SUP], Emeline Orillard[SUP] 9 [/SUP], Laura Mansi[SUP] 9 [/SUP], Anne-Laure Clairet[SUP] 10 [/SUP], Virginie Westeel[SUP] 5 [/SUP], Samuel Limat[SUP] 11 [/SUP], Maxime Dubois[SUP] 10 [/SUP], L?a Malinowski[SUP] 12 [/SUP], Louis Bohard[SUP] 12 [/SUP], Christophe Borg[SUP] 2 [/SUP], Catherine Chirouze[SUP] 13 [/SUP], Kevin Bouiller[SUP] 14 [/SUP]



Affiliations

Abstract

Adaptive Immune responses generated by SARS-CoV-2 virus in convalescent patients according to disease severity remain poorly characterized. To this end, we designed a prospective study (NCT04365322) that included 60 COVID-19 convalescent patients (1-month post infection) in two cohorts respectively entitled mild illness and severe pneumonia. The monitoring of peripheral immune responses was performed using IFNᵧ ELISpot assay. The serology index of each patient was investigated at the same time. Patients with severe pneumonia were older and had more comorbidities than patients with mild illness. T-cell responses in term of frequency and intensity were clearly distinct between mild illness and severe pneumonia patients. Furthermore, our results demonstrated that recent history of COVID-19 did not hamper viral memory T-cell pool against common viruses (Cytomegalovirus, Epstein-Barr-virus and Flu-virus). The presence of potent adaptive immunity even in patients who underwent severe pneumonia sustain the rationale for the development of protective therapeutics against SARS-CoV-2.

Keywords: Adaptive immunity; COVID-19; Coronavirus; Interferonᵧ; SARS-CoV-2; T-cells.
 
Back
Top Bottom